Page last updated: 2024-09-05

sb 203580 and c 1368

sb 203580 has been researched along with c 1368 in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (c 1368)	Trials (c 1368)	Recent Studies (post-2010) (c 1368)
3,489	4	1,137	6	0	4

Protein Interaction Comparison

Protein	Taxonomy	c 1368 (IC50)
Chain A, Serine/threonine-protein kinase 6	Homo sapiens (human)	0.042
Aurora kinase A	Homo sapiens (human)	0.042
Tyrosine-protein kinase Lck	Homo sapiens (human)	0.131
Insulin-like growth factor 1 receptor	Homo sapiens (human)	0.591
Tyrosine-protein kinase SYK	Homo sapiens (human)	0.887
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	0.386

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M	1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A	1

Other Studies

2 other study(ies) available for sb 203580 and c 1368

Article	Year
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51 Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases	2007
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2 Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase	2013

Article

Year

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007

A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013